MedTrace Logo

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT04176588 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2024-01-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug: Placebo Phase: Phase 3

Conditions

  • Moderately to Severely Active Ulcerative Colitis

Interventions

DRUG

Etrasimod

Drug:Etrasimod Tablet other name:APD334

DRUG

Placebo

Drug:placebo Tablet

Sponsors & Collaborators

  • Everstar Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Kaichun Wu · The First Affiliated Hospital of Fourth Military Medical University, PLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2024-07-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176588 on ClinicalTrials.gov